Communiqués Innovation Pharmaceuticals Inc.

Actions

IPIX

US45782D1000

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets Autres places de cotation 20:01:29 15/07/2026			Varia. 5j.	Varia. 1 janv.
0,001000 ^USD	+100,00%		+233,33%	-

01/02/24	Innovation Pharmaceuticals Inc. annonce la démission de membres de son conseil d'administration	CI
05/12/23	Alfasigma S.p.A. et Innovation Pharmaceuticals Inc. mettent fin à l'accord de licence exclusive	CI

Communiqués

28/08/23	Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024	AQ
21/06/23	Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	AQ
05/06/23	Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing	AQ
17/04/23	Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications	AQ
15/03/23	Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers	AQ
23/02/23	Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission	AQ
15/02/23	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
09/01/23	Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement	AQ
04/01/23	INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)	AQ
14/12/22	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis	AQ
13/12/22	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis	AQ
28/11/22	Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family	AQ
16/11/22	Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference	AQ
10/11/22	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
27/10/22	Innovation Pharmaceuticals - NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy 'Game-Changing Breakthrough'	AQ
26/10/22	NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"	AQ
04/10/22	Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin	AQ
28/09/22	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
16/09/22	New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals Brilacidin Presented at 2022 Military Health System Research Symposium	AQ
14/09/22	Innovation Pharmaceuticals Investment in BT BeaMedical Helping Advance New Surgical Laser Platform	AQ
08/08/22	Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox	AQ
05/08/22	Innovation Pharmaceuticals : Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox	PU
25/07/22	Innovation Pharmaceuticals - Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate	AQ
22/07/22	Innovation Pharmaceuticals : Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate	PU
28/06/22	Innovation Pharmaceuticals : Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium	PU